Literature DB >> 2717299

Recombinant erythropoietic growth factors as an alternative to erythrocyte transfusion for patients with "anemia of prematurity".

R D Christensen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2717299

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  4 in total

Review 1.  The cytokines are coming.

Authors:  K P Windebank
Journal:  Arch Dis Child       Date:  1990-11       Impact factor: 3.791

2.  Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.

Authors:  Srividya Neelakantan; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pediatr Int       Date:  2009-02       Impact factor: 1.524

Review 3.  Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

4.  Reducing donor exposure in preterm infants requiring multiple blood transfusions.

Authors:  A Wood; N Wilson; P Skacel; R Thomas; E Tidmarsh; C Yale; M de Silva
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-01       Impact factor: 5.747
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.